Novel semi‐replicative retroviral vector mediated double suicide gene transfer enhances antitumor effects in patient‐derived glioblastoma models

As glioblastomas are mostly localized infiltrative lesions, gene therapy based on the retroviral replicating vector (RRV) system is considered an attractive strategy. Combinations of multiple suicide genes can circumvent the limitations associated with each gene, achieving direct and synergistic cytotoxic effects, along with bystander cell killing. In this study, we constructed a semi‐and pseudotyped‐RRV (sp‐RRV) system harboring two suicide genes—herpes simplex virus type 1 thymidine kinase (TK) and yeast cytosine deaminase (CD)—to verify the dissemination and antitumor efficacy of our sp‐RRV system (spRRVe‐sEF1α‐TK/sRRVgp‐sEF1α‐CD) in seven patient-derived glioblastoma stem‐like cells (GSCs). Flow cytometry and high‐content analysis revealed a wide range of transduction efficiency and good correlation between the delivery of therapeutic genes and susceptibility to the prodrugs ganciclovir and 5‐fluorocytosine in patient‐derived GSCs in vitro. Intra‐tumoral delivery of spRRVe‐sEF1α‐TK/sRRVgp‐sEF1α‐CD, combined with prodrug treatment, synergistically inhibited cell proliferation and angiogenesis while increasing apoptosis and the depletion of tumor‐associated macrophages in orthotopic glioblastoma xenografts. Genomic profiling of patient‐derived GSCs revealed that the key genes preventing sp‐RRV infection and transmission were associated with cell adhesion, migration, development, differentiation, and proliferation. This is the first report demonstrating that a novel sp‐RRV‐mediated TK/CD double suicide gene transfer system has high oncolytic power against extremely heterogeneous and treatment‐refractory glioblastomas.